Tag: reconsent

Reconsent Strategies in DCT, eConsent and Remote Visit Models In the evolving landscape of clinical trials, particularly in fields such as schizophrenia clinical trials, reconsent strategies are becoming increasingly critical. This guide aims to provide clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU with a comprehensive walkthrough on implementing…

Read More “Reconsent Strategies in DCT, eConsent and Remote Visit Models” »

Corrective Measures for Eligibility, Dosing and Visit Deviations Corrective Measures for Eligibility, Dosing and Visit Deviations In clinical trials, maintaining compliance with the protocol is crucial to ensuring the validity of the study. Protocol deviations, such as eligibility, dosing, and visit deviations, necessitate corrective measures for the integrity of the clinical trial. This comprehensive guide…

Read More “Corrective Measures for Eligibility, Dosing and Visit Deviations” »

Documenting Reconsent Discussions and Updated Informed Consent Forms Documenting Reconsent Discussions and Updated Informed Consent Forms In the domain of clinical trials, particularly those regulated by the FDA, EMA, and MHRA, maintaining robust ethical standards is paramount. One of the critical components of adhering to these ethical standards is the process of informed consent. This…

Read More “Documenting Reconsent Discussions and Updated Informed Consent Forms” »

IRB/IEC Expectations for Reconsent Following Major Deviations IRB/IEC Expectations for Reconsent Following Major Deviations In clinical research, maintaining compliance with ethical and regulatory standards is paramount. The role of Institutional Review Boards (IRB) and Independent Ethics Committees (IEC) is critical in ensuring participant safety and informed consent throughout the clinical trial process. This article provides…

Read More “IRB/IEC Expectations for Reconsent Following Major Deviations” »

Reconsenting Subjects After Protocol Deviations: When, Why and How Reconsenting Subjects After Protocol Deviations: When, Why and How The integrity of clinical trial research is paramount, and protocol deviations can jeopardize this integrity. Reconsenting subjects after such deviations is a critical process that clinical operations, regulatory affairs, and medical affairs professionals must navigate carefully. This…

Read More “Reconsenting Subjects After Protocol Deviations: When, Why and How” »